JANSSEN ABIRATERONE abiraterone acetate 250 mg tablet bottle

Χώρα: Αυστραλία

Γλώσσα: Αγγλικά

Πηγή: Department of Health (Therapeutic Goods Administration)

Δραστική ουσία:

abiraterone acetate, Quantity: 250 mg

Διαθέσιμο από:

Janssen-Cilag Pty Ltd

INN (Διεθνής Όνομα):

Abiraterone acetate

Φαρμακοτεχνική μορφή:

Tablet

Σύνθεση:

Excipient Ingredients: colloidal anhydrous silica; povidone; microcrystalline cellulose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; croscarmellose sodium

Οδός χορήγησης:

Oral

Μονάδες σε πακέτο:

120 tablets

Τρόπος διάθεσης:

(S4) Prescription Only Medicine

Θεραπευτικές ενδείξεις:

JANSSEN ABIRATERONE is indicated in combination with prednisone or prednisolone for the treatment of: ? newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT), or ? patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) or ? patients with mCRPC who have received prior chemotherapy containing a taxane.

Περίληψη προϊόντος:

Visual Identification: White to off-white, oval shaped tablets with "AA250" on one side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Καθεστώς αδειοδότησης:

Registered

Ημερομηνία της άδειας:

2012-03-01